Course Experts: Houry Leblebjian, PharmD, BCOP and Omar Marzouk, PharmD

Course Description: This course describes recent recommendations for newly diagnosed myeloma and evaluates the role of approved treatment options in relapsed/refractory multiple myeloma.

[DFCI_KEYWORDS] Myeloma, CRAB Criteria, Hypercalcemia, Extramedullary Plasmacytomas, Hyperviscosity, Hypogammaglobulinemia, Amyloidosis, NCCN (National Comprehensive Cancer Network), Autologous Stem Cell Transplant, Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, GRIFFIN Study, LYRA Trial, Panobinostat, Selinexor, Belantamab Mafodotin, CAR-T Therapy